Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-05 15:15 |
Schedule 13G/A filed by Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Manag…
|
English | 36.0 KB | ||
| 2023-02-01 00:54 |
Entered into a Sales Agreement pursuant to which the company may offer and sell…
|
English | 196.1 KB | ||
| 2023-02-01 00:54 |
Entered into a Sales Agreement pursuant to which the company may offer and sell…
|
English | 36.0 KB | ||
| 2023-02-01 00:49 |
Prospectus Supplement relating to the sale of up to $50,000,000 ordinary shares…
|
English | 355.2 KB | ||
| 2023-02-01 00:49 |
Prospectus Supplement relating to the sale of up to $50,000,000 ordinary shares…
|
English | 35.9 KB | ||
| 2023-01-23 14:59 |
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape O…
|
English | 82.7 KB | ||
| 2023-01-23 14:59 |
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape O…
|
English | 36.0 KB | ||
| 2022-12-06 14:59 |
Compugen’s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Prel…
|
English | 122.1 KB | ||
| 2022-12-06 14:59 |
Compugen’s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Prel…
|
English | 36.1 KB | ||
| 2022-12-02 14:59 |
Bayer notified the “Company that it has resolved to terminate, effective as of …
|
English | 61.9 KB | ||
| 2022-12-02 14:59 |
Bayer notified the “Company that it has resolved to terminate, effective as of …
|
English | 35.9 KB | ||
| 2022-12-01 14:59 |
COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Ant…
|
English | 66.9 KB | ||
| 2022-12-01 14:59 |
COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Ant…
|
English | 36.1 KB | ||
| 2022-11-29 14:59 |
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
|
English | 82.5 KB | ||
| 2022-11-29 14:59 |
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
|
English | 35.9 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
